Bionoid Pharma : Interim Financial Statements for Period Ending Sept. 30 - 2021

Bionoid Pharma, Inc.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

For the three and nine months ended September 30, 2021 and 2020

	Contents
Condensed Consolidated Interim Statements of Financial Position	3
Condensed Consolidated Interim Statements of Operations and Comprehensive	4
Income (Loss)
Condensed Consolidated Interim Statements of Changes in Equity	5
Condensed Consolidated Interim Statements of Cash Flows	6

Page 1 of 20

MANAGEMENT'S COMMENTS ON UNAUDITED INTERIM

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated interim financial statements of Bionoid Pharma, Inc. (the "Company") have been prepared by and are the responsibility of the Company's management. The unaudited condensed consolidated interim financial statements are prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS") and reflect management's best estimates and judgment based on information currently available. The Company's independent auditor has not performed a review of these unaudited condensed consolidated interim financial statements.

Page 2 of 20

Bionoid Pharma, Inc.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS OF FINANCIAL POSITION (UNAUDITED)

Expressed in U.S. Dollars

	September 30,	December 31,
	2021	2020
Assets
Current assets	$5,052
Cash and cash equivalents	$630
Property, plant and equipment	1,473	3,454
Accounts receivable	-	-
Patents, trademarks	24,185	24,185
Investment in shares	60,142	95,466
Total current assets	90,852	123,735
Total assets	$90,852	$123,735
Liabilities and shareholders' equity
Current liabilities	$133,652
Loans payable	$164,637
Accounts payable	2,444	-
Other current liabilities	4,509	-
Total current liabilities	140,605	164,637
Total liabilities	$140,605	$164,637
Shareholders' equity	19,117,093
Contributed surplus	19,085,761
Shareholders' contribution	9,560	9,560
Accumulated deficit	(20,625,223)	(20,579,745)
Common stock	1,448,817	1,443,522
Total shareholders' equity	(49,753)	(40,902)
Total liabilities and shareholders' equity	$90,852	$123,735
On behalf of the Board:
(signed) "Wayne Cockburn"		Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page 3 of 6

Bionoid Pharma, Inc.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Expressed in U.S. Dollars

	Three months ended		Nine months ended
	September 30,		September 30,
	2021	2020	2021	2020
Revenue	$18,359		$88,526
Gross sales	13,3341	30,657
Less Cost of sales	(2,276)	(3,431)	(23,619)	(13,585)
Gross profit before operating expenses	16,083	5,093	64,907	17,072
Operating expenses
450		639
Dues and subscriptions	438	-
Office expenses	1,941	367	3,265	251
Professional fees	2,678	75	9,742	6,000
Other expenses	10,851	4,058	13,618	43,302
	15,920	4,938		27,264	49,453
Gross income (loss)	$163	$155	$37,643	$(32,381)
Other expenses	$(55,295)	-
Loss on sale of shares	$(102,580)	-
Restatement of value of shares					$(406,330)
Net income (loss)	$(55,132)	$155	$64,786	$(455,783)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page 4 of 6

Bionoid Pharma, Inc.

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

Expressed in U.S. Dollars

Balance, December 31, 2020

Balance, March 31, 2021

Shares issued for employment agreements Shares issued for distribution agreement Shares issued upon conversion of debt

Balance, September 30, 2021

Capital Stock								Total
(Number of		Capital		Contributed				Shareholder's
Shares)		Stock ($)		Surplus		Deficit		Equity (Deficit)
38,358	$	1,443,522	$	19,085,761	$	(20,579,745)	$	(40,902)
38,358	$	1,443,522	$	19,085,761	$	(20,546,157)	$	473,686
5,440,412		544		9,383
41,803,126		4,180		72,097
5,712,714		571		9,852
52,994,610	$	1,448,817	$	19,177,093	$	(20,570,091)	$	780

The accompanying notes are an integral part of these condensed consolidated interim financial statements.